| Budget Amount *help |
¥195,130,000 (Direct Cost: ¥150,100,000、Indirect Cost: ¥45,030,000)
Fiscal Year 2018: ¥35,100,000 (Direct Cost: ¥27,000,000、Indirect Cost: ¥8,100,000)
Fiscal Year 2017: ¥38,480,000 (Direct Cost: ¥29,600,000、Indirect Cost: ¥8,880,000)
Fiscal Year 2016: ¥38,870,000 (Direct Cost: ¥29,900,000、Indirect Cost: ¥8,970,000)
Fiscal Year 2015: ¥39,650,000 (Direct Cost: ¥30,500,000、Indirect Cost: ¥9,150,000)
Fiscal Year 2014: ¥43,030,000 (Direct Cost: ¥33,100,000、Indirect Cost: ¥9,930,000)
|
|---|
| Outline of Final Research Achievements |
Immune status varies among cancer patients and is correlated with responses to various cancer therapies including immunotherapy. However its mechanisms and outcome have not been understood well. In this study, we revealed immunological subtypes of various human cancers using a variety of new technologies such as comprehensive genetic, immunological, and microbial analyses. In addition, we identified various chemicals and antibodies capable of augmenting anti-tumor immunity using mouse tumor models and newly developed humanized mice. These results contribute not only to advance of human tumor immunology, but also to development of effective combination immunotherapy.
|
